Literature DB >> 10853007

Thrombotic thrombocytopenic purpura and clopidogrel--a need for new approaches to drug safety.

A J Wood.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10853007     DOI： 10.1056/NEJM200006153422410

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

Review 1.  Manufacturer's drug interaction and postmarketing adverse event data: what are appropriate uses?

Authors:  W K Kraft; S A Waldman
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 2.  Methods and systems to detect adverse drug reactions in hospitals.

Authors:  P A Thürmann
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

3.  Comparing time to adverse drug reaction signals in a spontaneous reporting database and a claims database: a case study of rofecoxib-induced myocardial infarction and rosiglitazone-induced heart failure signals in Australia.

Authors:  Izyan A Wahab; Nicole L Pratt; Lisa M Kalisch; Elizabeth E Roughead
Journal:  Drug Saf       Date:  2014-01       Impact factor: 5.606

4.  Postmarketing adverse drug reactions: A duty to report?

Authors:  Eran Klein; Dennis Bourdette
Journal:  Neurol Clin Pract       Date:  2013-08

5.  Detection of adverse drug reactions in a neurological department: comparison between intensified surveillance and a computer-assisted approach.

Authors:  Petra A Thuermann; Roland Windecker; Joachim Steffen; Markus Schaefer; Ute Tenter; Erich Reese; Hermann Menger; Klaus Schmitt
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

6.  Low ADAMTS-13 in plavix induced thrombotic thrombocytopenic purpura.

Authors:  Long Bao Cao; Christopher Jones; Assad Movahed
Journal:  World J Clin Cases       Date:  2013-04-16       Impact factor: 1.337

7.  Thrombotic Thrombocytopenic Purpura associated with Clopidogrel: a case report and review of the literature.

Authors:  Taleb Azarm; Ayatollah Sohrabi; Hamid Mohajer; Arezou Azarm
Journal:  J Res Med Sci       Date:  2011-03       Impact factor: 1.852

8.  Clopidogrel-induced thrombotic thrombocytopenic purpura-hemolytic uremic syndrome after coronary artery stenting.

Authors:  Shawn M Manor; Gregory S Guillory; Suresh P Jain
Journal:  Pharmacotherapy       Date:  2004-05       Impact factor: 4.705
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.